For informational and research purposes only. Not medical advice. Content is aggregated from public sources. Always consult a qualified healthcare provider.
Performance & Growth Hormone · Comparison

Ghrelin vs Hexarelin

A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

GhrelinHexarelin
CategoryPerformance & Growth HormonePerformance & Growth Hormone
Also known asGHRL, growth hormone-releasing peptide endogenous, ghrelinergic peptide, acyl ghrelinExamorelin, EP 23905, MF-6003
EvidenceInvestigational (in trials)Preclinical only
Dosing range0.5mcg/kg–2mcg/kg mcg/kg, IV or SC bolus; endogenous levels peak pre-meal50mcg–200mcg mcg, 1–3x daily (cycling recommended to prevent desensitization)
AdministrationIntravenous (research), Subcutaneous injectionSubcutaneous injection, Intramuscular injection
Key side effectsAppetite stimulation, Transient hyperglycemia, Water retention, GH pulse stimulationCortisol elevation, Prolactin elevation, Water retention, Increased appetite
Cited sources2 references1 reference

Key differences

  • Evidence level differs: Ghrelin is investigational (in trials), while Hexarelin is preclinical only.
  • Administration: Ghrelin — Intravenous (research), Subcutaneous injection; Hexarelin — Subcutaneous injection, Intramuscular injection.
  • Dosing units differ: Ghrelin is dosed in mcg/kg, Hexarelin in mcg — they operate at different scales.
  • Frequency: Ghrelin is typically IV or SC bolus; endogenous levels peak pre-meal; Hexarelin is 1–3x daily (cycling recommended to prevent desensitization).
  • Research depth: this profile cites 2 sources for Ghrelin vs 1 for Hexarelin.

How each works

Ghrelin

Ghrelin was discovered in 1999 as the endogenous ligand for the GHS-R1a receptor. Its acylated form activates GH release from the pituitary, stimulates appetite via NPY/AgRP hypothalamic neurons, and modulates energy homeostasis and fat storage. The des-acyl form (majority of circulating ghrelin) lacks GHS-R1a activity but has independent cardiovascular and cellular effects.

Hexarelin

Hexarelin produces dose-dependent GH release significantly greater than GHRP-6 or Ipamorelin. It also has direct cardioprotective effects via CD36 receptor binding, independent of GH — making it unique among GHRPs. Studies show protection from ischemic cardiac injury and myocardial fibrosis reduction in animal models. Desensitization occurs with chronic continuous use.

Read the full Ghrelin profileRead the full Hexarelin profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.